Back
Top 1%
14.8%
Top 5%
14.8%
Top 1.0%
9.1%
Top 66%
7.9%
Top 0.7%
6.5%
Top 12%
3.9%
Top 2%
3.9%
Top 66%
3.9%
#1
2.8%
Top 2%
2.8%
Top 3%
2.0%
Top 2%
2.0%
Top 7%
1.6%
Top 13%
1.6%
Top 6%
1.4%
Top 0.9%
1.4%
Top 4%
1.2%
Top 5%
1.0%
Top 7%
0.7%
Top 4%
0.7%
Top 7%
0.7%
Top 10%
0.7%
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
2026-01-06
oncology
Title + abstract only
View on medRxiv
Show abstract
In approximately one third of patients, resected head and neck squamous cell carcinoma will recur. We postulated that the induction of tumor neoantigen-specific T cell responses could prevent relapse. To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens delivered by a Modified Vaccinia Ankara virus viral vector. We tested TG4050 as single agent in a randomized phase I trial. We found that of 16 evaluable...
Predicted journal destinations
1
Cancers
57 training papers
2
Nature Communications
483 training papers
3
Frontiers in Oncology
34 training papers
4
PLOS ONE
1737 training papers
5
Clinical Cancer Research
22 training papers
6
eLife
262 training papers
7
Proceedings of the National Academy of Sciences
100 training papers
8
Scientific Reports
701 training papers
9
Cell Reports
25 training papers
10
Cancer Medicine
17 training papers
11
British Journal of Cancer
22 training papers
12
BMC Cancer
21 training papers
13
Frontiers in Immunology
140 training papers
14
JAMA Network Open
125 training papers
15
iScience
74 training papers
16
The Journal of Immunology
19 training papers
17
Journal of Clinical Investigation
50 training papers
18
Cell Reports Medicine
49 training papers
19
International Journal of Molecular Sciences
39 training papers
20
Science Translational Medicine
40 training papers
21
Communications Medicine
63 training papers
22
Nature
58 training papers